Technical Analysis for BDSI - BioDelivery Sciences International, Inc.

Grade Last Price % Change Price Change
grade C 4.52 -1.09% -0.05
BDSI closed down 1.09 percent on Monday, May 20, 2019, on 57 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BDSI trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal -1.09%
Lower Bollinger Band Walk Weakness -1.09%
Stochastic Reached Oversold Weakness -1.09%
Below Lower BB Weakness -1.09%

Older signals for BDSI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapeutics in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) drug delivery technology that consists of a small, bi-layered erodible polymer film for application to the buccal mucosa in the development of its products. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer; BEMA Buprenorphine that is in Phase III trial for the treatment of moderate to severe chronic pain in a mixed opioid naïve and opioid experienced population; BEMA Buprenorphine/Naloxone, which is in development stage for the treatment of opioid dependence; and BEMA Granisetron for the prevention of nausea and vomiting associated with cancer therapies. The company has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Cancer Pharmaceutical Pain Drugs Pain Management Euphoriants Morphinans Cancer Therapies Opioids Nausea Vomiting Fentanyl Severe Chronic Pain Buprenorphine Drug Delivery Technology Drug Rehabilitation Opioid Opioid Antagonists Breakthrough Pain Naloxone
Is BDSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.3732
52 Week Low 2.225
Average Volume 1,017,054
200-Day Moving Average 3.9245
50-Day Moving Average 4.9078
20-Day Moving Average 4.8245
10-Day Moving Average 4.811
Average True Range 0.1983
ADX 16.24
+DI 14.4824
-DI 27.1987
Chandelier Exit (Long, 3 ATRs ) 4.6151
Chandelier Exit (Short, 3 ATRs ) 5.0049
Upper Bollinger Band 5.0969
Lower Bollinger Band 4.5521
Percent B (%b) -0.06
BandWidth 11.292362
MACD Line -0.0652
MACD Signal Line -0.0265
MACD Histogram -0.0388
Fundamentals Value
Market Cap 250.75 Million
Num Shares 55.5 Million
EPS 0.03
Price-to-Earnings (P/E) Ratio 150.67
Price-to-Sales 3.69
Price-to-Book 6.22
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.79
Resistance 3 (R3) 4.78 4.69 4.75
Resistance 2 (R2) 4.69 4.62 4.69 4.73
Resistance 1 (R1) 4.60 4.58 4.56 4.61 4.71
Pivot Point 4.51 4.51 4.48 4.51 4.51
Support 1 (S1) 4.42 4.44 4.38 4.43 4.33
Support 2 (S2) 4.33 4.40 4.33 4.31
Support 3 (S3) 4.24 4.33 4.30
Support 4 (S4) 4.25